Research

Learn about published research as well as leading-edge basic and translational research initiatives from St. Jude laboratories.

A moving target: Taking aim at the shift and drift of influenza viruses

Daniel Darnell

How close are we to a flu pandemic? Read how it could happen and what researchers are doing to prevent it.

Blazing through new territory to fight a devastating neurodegenerative disease

St. Jude Communications Department

Read how researchers have found a path to control coenzyme A and possibly prevent a devastating neurodegenerative disease.

Can obesity give influenza more time to spread and make vaccines less effective?

Stacey Schultz-Cherry, PhD

St. Jude researchers, led by Dr. Stacey Schultz-Cherry, are asking questions about potential association between flu severity and the obesity epidemic.

Gut microbiome sequencing opens new possibilities for predicting infection in leukemia patients

St. Jude Communications Department

Researchers identify intestinal microbiota that may predict infection risk during chemotherapy in pediatric ALL patients. Learn about the gut microbiome.

New drug for a rare disorder: How will Gamifant’s approval affect HLH treatment?

Melissa Hines, MD

HLH, a rare disorder of the immune system, is caused by a buildup of proteins responding to infection. Read about a new treatment that limits that buildup.

Tumor microenvironment switches from homely to hostile when this process is turned off

Douglas R. Green, PhD

Researchers learn how this housekeeper for cancer cells turns into a cancer house killer. Learn how targeting LAP could promote an anti-tumor response and slow tumor growth.

New algorithm could help us better understand cancer at its genetic level

Xiang Chen, PhD

This new cancer algorithm shows possible precision options for cancer treatment.

Cancer-fighting ninja protein may offer clue to create self-harming cancer cells

Tudor Moldoveanu, PhD

This shape-shifting cipher of the cell may hold the key to curing cancer through causing cancer cells to kill themselves.

Will Mother Nature deal a deadly hand with influenza virus?

Robert Webster, PhD

How close are we to another deadly influenza virus pandemic? Read about how scientists are figuring out how to prevent the next catastrophe.

Targeted therapy larotrectinib could make tumors with rare NTRK fusion genes less lethal

Alberto Pappo, MD

Newly approved Vitrakvi (larotrectinib) scored high patient response rates by inhibiting a rare chromosomal abnormality that drives tumor growth.